Molecular Diagnostics For Sexually Transmitted Diseases Market Size, Share, Trends, & Industry Analysis Report By Product (Instruments & Services, Consumables, and Software), By Application, By Technology, By Region – Market Forecast, 2025–2034

The global molecular diagnostics for sexually transmitted diseases market size is expected to reach USD 7.85 billion by 2034, according to a new study by Polaris Market Research. The report “Molecular Diagnostics for Sexually Transmitted Diseases Market Size, Share, Trends, & Industry Analysis Report By Product (Instruments & Services, Consumables, and Software), By Application, By Technology, By Region – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Molecular diagnostics for sexually transmitted diseases (STDs) involves advanced laboratory techniques that pinpoint the genetic material, such as DNA or RNA, of the microorganisms causing these infections. Unlike older methods that might look for antibodies or grown cultures, molecular tests directly identify the pathogen itself. This allows for highly accurate and sensitive detection, often enabling diagnosis even in the early stages of an infection or when symptoms are not yet present, which is crucial for timely treatment and preventing further spread.

The market for molecular diagnostics for STDs is experiencing significant growth due to the rising global incidence of STDs, which necessitates more effective and rapid diagnostic solutions to manage public health challenges. Additionally, ongoing technological advancements in molecular testing, including the development of multiplex assays that can detect multiple pathogens simultaneously, are enhancing testing efficiency and accessibility. The increasing awareness among healthcare professionals and the general public about the importance of early and accurate STD diagnosis also contributes to the expanding adoption of these advanced diagnostic methods.

Molecular Diagnostics for Sexually Transmitted Diseases Market Report Highlights:

By product, the consumables segment, encompassing reagents and kits, holds the largest share due to its essential role in every molecular STD test.

Based on application, the CT/NG testing segment dominated in 2024 as these are among the most prevalent STDs worldwide.

In terms of technology, the laboratory testing segment held the largest share in 2024, supported by the established infrastructure of centralized labs.

By region, North America dominated the molecular diagnostics for sexually transmitted diseases market revenue share in 2024. Asia Pacific is projected to witness the fastest growth during the forecast period.

A few key players in the market include Abbott Laboratories; F. Hoffmann-La Roche AG (Roche Diagnostics); bioMérieux SA; QIAGEN N.V.; Hologic Inc.; Becton, Dickinson and Company (BD); Siemens Healthineers AG; DiaSorin S.p.A.; Thermo Fisher Scientific Inc.; QuidelOrtho Corporation; and Seegene Inc.

Polaris Market Research has segmented the molecular diagnostics for sexually transmitted diseases market report on the basis of product, application, technology, and region:

By Product Outlook (Revenue – USD Billion, 2020–2034)

Instruments & Services

Consumables

Software

By Application Outlook (Revenue – USD Billion, 2020–2034)

CT/NG Testing

Syphilis Testing

Gonorrhea Testing

HSV Testing

HPV Testing

HIV Testing

Trichomonas

Ureaplasma + Mycoplasma

Others

By Technology Outlook (Revenue – USD Billion, 2020–2034)

Laboratory Testing

Commercial/Private Labs

Public Health Labs

PoC testing

By Regional Outlook (Revenue – USD Billion, 2020–2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America Show more